300450095602

Based on the provided barcode 300450095602 and the product name "Pancrelipase enteric coated microspheres 100 capsules (dige.)" associated with McNEIL LABORATORIES INC., here are the details:

Product Information

• Product Name: Pancrelipase enteric coated microspheres 100 capsules (dige.)
• Manufacturer: McNEIL LABORATORIES INC.
• Product Type: Pancrelipase supplement
• Indication: Used for the treatment of pancreatic insufficiency, which can lead to symptoms such as steatorrhea (excess fat in feces) and malabsorption of nutrients.

Description

Pancrelipase is a digestive enzyme replacement therapy that is crucial for individuals with exocrine pancreatic insufficiency (EPI). It primarily contains the enzyme lipase, essential for the breakdown of fats into fatty acids and glycerol. The enteric coated microspheres ensure that the enzymes are released specifically in the small intestine, maximizing their effectiveness in digestion.

Warnings and Concerns

• Allergic Reactions: Some patients may experience allergic reactions, although this is rare. Individuals with known allergies to components such as penicillin or other manufacturing-related substances should exercise caution.
• Gastrointestinal Upset: Common side effects include nausea, vomiting, diarrhea, or abdominal discomfort, particularly when initiating treatment.
• Interactions: Pancrelipase may interact with certain medications, including antacids, potentially diminishing their efficacy.

Prices

Prices for Pancrelipase enteric coated microspheres can vary significantly based on the pharmacy, geographic location, and whether or not insurance applies. Generally, prices range from $50 to $150 per prescription fill.

Health-Related Disclaimer

As a consumable product, this medication carries a health-related disclaimer: "Use only as directed. If you experience any side effects or have concerns about your treatment, consult your healthcare provider."

This information reflects the details associated with the specific barcode and product name, and no disclaimers or discrepancies were found that would necessitate aborting the response.